ANI Pharmaceuticals Files 8-K
Ticker: ANIP · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1023024
| Field | Detail |
|---|---|
| Company | Ani Pharmaceuticals Inc (ANIP) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing
TL;DR
ANI Pharma filed an 8-K, standard update, no major news in this snippet.
AI Summary
ANI Pharmaceuticals, Inc. filed an 8-K on September 16, 2024, reporting other events and financial statements. The filing does not contain specific details on new events or financial figures within the provided text, but indicates a standard reporting update.
Why It Matters
This filing serves as a public record of significant corporate events or financial updates for ANI Pharmaceuticals, Inc., providing transparency to investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain information indicating immediate or significant risk.
Key Players & Entities
- ANI PHARMACEUTICALS, INC. (company) — Registrant
- September 16, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 001-31812 (identifier) — Commission File Number
- 58-2301143 (identifier) — I.R.S. Employer Identification No.
- 210 Main Street West Baudette, Minnesota 56623 (address) — Principal executive offices
- 218 634-3500 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for ANI Pharmaceuticals, Inc.?
The 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating it reports on 'Other Events' and 'Financial Statements and Exhibits'.
On what date was this 8-K filing reported?
The date of the report, and the date of the earliest event reported, is September 16, 2024.
In which state is ANI Pharmaceuticals, Inc. incorporated?
ANI Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for ANI Pharmaceuticals, Inc.?
The principal executive offices are located at 210 Main Street West, Baudette, Minnesota 56623.
Does the provided text detail any specific 'Other Events' or financial information?
No, the provided text of the 8-K filing only indicates that 'Other Events' and 'Financial Statements and Exhibits' are being reported, but does not specify the details of these items.
Filing Stats: 442 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2024-09-16 09:13:56
Filing Documents
- ani-20240916.htm (8-K) — 27KB
- anipclosing-20240916xexx991.htm (EX-99.1) — 29KB
- imagea.jpg (GRAPHIC) — 29KB
- 0001023024-24-000088.txt ( ) — 224KB
- ani-20240916.xsd (EX-101.SCH) — 2KB
- ani-20240916_lab.xml (EX-101.LAB) — 21KB
- ani-20240916_pre.xml (EX-101.PRE) — 12KB
- ani-20240916_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On September 16, 2024, ANI Pharmaceuticals, Inc., issued a press release announcing the completion of the previously announced acquisition of Alimera Sciences, Inc., pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.
01 Exhibits
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated September 16 , 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 16, 2024 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer